
Opinion|Videos|May 21, 2025
Ideal Candidates for Bronchiectasis Surgeries
Panelists discuss how ideal candidates for bronchiectasis surgery have localized disease on CT scan and bronchoscopy, adequate pulmonary function (orced expiratory volume in 1 second > 40%), and whose infections are controlled prior to surgery.
Advertisement
Episodes in this series

Clinical Brief: Surgical Management of Bronchiectasis
Main Discussion Topics
- Ideal surgical candidates have localized disease and adequate pulmonary function.
- Preoperative optimization of infection status is crucial for successful outcomes.
- Collaboration between pulmonologists and surgeons is essential during patient selection.
Key Points for Physicians
- Surgical consideration criteria:
- Forced expiratory volume in 1 second and diffusing capacity of the lung for carbon monoxide values of greater than 40% to minimize morbidity and mortality
- Disease localized to a segment or lobe on CT imaging
- Identification of affected area via bronchoscopy
- Adequate control of active infection before surgery
- Common indications include:
- Refractory infections despite optimal medical management
- Intolerance to long-term antibiotics
- Aspergillus fungal masses
- Macrolide-resistant nontuberculous mycobacteria with localized infection
- Hemoptysis (after initial management with bronchoscopy/embolization)
Notable Insights
Complete resection of affected areas can lead to significant symptom improvement and reduced need for ongoing medications when disease is localized.
Clinical Significance
Surgical management represents an important option for select patients with bronchiectasis with localized disease when medical management has failed to control symptoms or infections.
Advertisement
Related to this article

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5

